Erratum to: High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy-resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor

No authors listed

Published Erratum

No authors listed. Neuro Oncol. 2025.

. 2025 Jul 25:noaf150.

doi: 10.1093/neuonc/noaf150. Online ahead of print.

No abstract available

Erratum for

High-resolution proteomic analysis of medulloblastoma clinical samples identifies therapy resistant subgroups and MYC immunohistochemistry as a powerful outcome predictor.
Delaidelli A, Burwag F, Ben-Neriah S, Suk Y, Shyp T, Kosteniuk S, Dunham C, Cheng S, Okonechnikov K, Schrimpf D, von Deimling A, Ellezam B, Perreault S, Singh S, Hawkins C, Kool M, Pfister SM, Steidl C, Hughes C, Korshunov A, Sorensen PH. Delaidelli A, et al. Neuro Oncol. 2025 Mar 5:noaf046. doi: 10.1093/neuonc/noaf046. Online ahead of print. Neuro Oncol. 2025. PMID: 40040502